KoRV Envelope Glycoproteins for NK Cell Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods face challenges in efficiently and stably modifying certain cell types, such as hematopoietic and immune cells, due to low transduction efficiency and the need for pre-activation of NK cells, which limits the effectiveness of viral vectors like lentiviral vectors pseudotyped with BaEV Env.
Innovation Solution
The use of Koala Retrovirus (KoRV) Envelope glycoproteins, specifically KoRVA, KoRVB, or their combination (KoRVAB), to create pseudotyped lentiviral vector particles that enable efficient transduction of NK cells without the need for pre-activation, by removing the fusion inhibitory R-peptide and using them in expression vectors, cassettes, or viral vector particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If lentiviral vectors pseudotyped with BaEV Env are used for gene transfer, then stable genetic modification of cells is achieved, but transduction efficiency in NK cells and other immune cells remains low and pre-activation is required
Solution Approach 1:
The invention changes the envelope glycoprotein parameter from BaEV Env to KoRV Env (specifically KoRVA, KoRVB, or KoRVAB), which fundamentally alters the transduction properties. This parameter change enables efficient transduction of NK cells and other immune cells without requiring pre-activation, directly resolving the technical contradiction between transduction efficiency and operational complexity
Solution Approach 2:
The invention uses pseudotyping, where the envelope glycoproteins of the lentiviral vector are replaced with KoRV Env glycoproteins. This copying of the envelope structure from a different virus (KoRV) allows the vector to acquire new target cell specificity, enabling efficient transduction of immune cells that were previously difficult to transduce
2Stability of the object's composition
If viral vectors are used for permanent and stable gene transfer, then stable genetic modification is achieved, but insertional mutagenesis may occur during optimization
Solution Approach 1:
The KoRV Env pseudotyping acts as an intermediary that enables stable gene transfer while reducing harmful effects. By modifying the envelope glycoproteins, the vector achieves better control over transduction efficiency and cell specificity, which allows for optimized delivery conditions that minimize insertional mutagenesis risks while maintaining stable genetic modification
3Productivity
If conventional transfection methods are used, then genetic manipulation is achieved, but efficiency varies and toxicity and off-target effects occur
Solution Approach 1:
The invention replaces mechanical/chemical transfection methods with a viral vector-based biological system. The KoRV Env-pseudotyped lentiviral vectors provide a more controlled and efficient gene delivery mechanism that reduces toxicity and off-target effects compared to conventional transfection methods like electroporation, while achieving stable genetic manipulation
Data Source
AI summary
The present invention relates to an expression vector, an expression cassette or a pseudotyped viral vector particle comprising at least one nucleic acid encoding at least one Koala Retrovirus (KoRV) Envelope glycoprotein (Env), related nucleic acids, pseudotyped viral vector particles, mammalian packaging cell lines, transduced mammalian cells as well as related methods and uses.